1.Liu Y, Xie Z*, Zhao D, Zhu J, Mao F, Tang S, Xu H, Luo C, Geng M, Huang M, Li J. Development of the First Generation of Disulfide-Based Subtype-Selective and Potent Covalent Pyruvate Dehydrogenase Kinase 1 (PDK1) Inhibitors. J Med Chem. 2017; 60(6):2227-2244.
2.Xie Z, Liu H, Geng M. Targeting sphingosine-1-phosphate signaling for cancer therapy. Sci China Life Sci. 2017; 60(6):585-600.
3. Sun W, Xie Z*, Liu Y, Zhao D, Wu Z, Zhang D, Lv H, Tang S, Jin N, Jiang H, Tan M, Ding J, Luo C, Li J, Huang M, Geng M.JX06 selectively inhibits pyruvate dehydrogenase kinase PDK1 by a covalent cysteine modification. Cancer Res. 2015, 75（22）：4923-4936.
4.Xie Z, Lee YH, Boeke M, Jilaveanu LB, Liu Z, Bottaro DP, Kluger HM, Shuch B. MET Inhibition in Clear Cell Renal Cell Carcinoma. J Cancer. 2016;7(10):1205-14.
5.Bi M, Zhao S, Said JW, Merino MJ, Adeniran AJ, Xie Z, Nawaf CB, Choi J, Belldegrun AS, Pantuck AJ, Kluger HM, Bilgüvar K, Lifton RP, Shuch B. Genomic characterization of sarcomatoid transformation in clear cell renal cell carcinoma. Proc Natl Acad Sci U S A. 2016，25（735）：1-6.
6.Sun W, Zhang X, Ding X, Li H, Geng M, Xie Z*, Wu H, Huang M. Lactate dehydrogenase B is associated with the response to neoadjuvant chemotherapy in oral squamous cell carcinoma. PLoS One. 2015; 14; 10(5):e0125976.
7.Zhu J, Wu YN, Zhang W, Zhang XM, Ding X, Li HQ, Geng M, Xie ZQ*, Wu HM. Monocarboxylate transporter 4 facilitates cell proliferation and migration and is associated with poor prognosis in oral squamous cell carcinoma patients. PLoS One. 2014; 30;9(1):e87904.
8.Meng T, Zhang D, Xie Z, Yu T, Wu S, Wyder L, Regenass U, Hilpert K, Huang M, Geng M, Shen J. Discovery and optimization of 4,5-diarylisoxazoles as potent dual inhibitors of pyruvate dehydrogenase kinase and heat shock protein 90. J Med Chem. 2014; 11;57(23):9832-43. |
